621 related articles for article (PubMed ID: 9865731)
21. Effects of bicistronic lentiviral vector-mediated herpes simplex virus thymidine kinase/ganciclovir system on human lens epithelial cells.
Yang J; Liu TJ; Lu Y
Curr Eye Res; 2007 Jan; 32(1):33-42. PubMed ID: 17364733
[TBL] [Abstract][Full Text] [Related]
22. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET.
Tseng JC; Zanzonico PB; Levin B; Finn R; Larson SM; Meruelo D
J Nucl Med; 2006 Jul; 47(7):1136-43. PubMed ID: 16818948
[TBL] [Abstract][Full Text] [Related]
23. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.
Toda M; Martuza RL; Rabkin SD
Gene Ther; 2001 Feb; 8(4):332-9. PubMed ID: 11313808
[TBL] [Abstract][Full Text] [Related]
24. Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy.
Miura F; Moriuchi S; Maeda M; Sano A; Maruno M; Tsanaclis AM; Marino R; Glorioso JC; Yoshimine T
Gene Ther; 2002 Dec; 9(24):1653-8. PubMed ID: 12457278
[TBL] [Abstract][Full Text] [Related]
25. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma.
Tsuchiyama T; Kaneko S; Nakamoto Y; Sakai Y; Honda M; Mukaida N; Kobayashi K
Cancer Gene Ther; 2003 Apr; 10(4):260-9. PubMed ID: 12679798
[TBL] [Abstract][Full Text] [Related]
26. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
27. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs.
Wildner O; Hoffmann D; Jogler C; Uberla K
Cancer Gene Ther; 2003 Oct; 10(10):791-802. PubMed ID: 14502232
[TBL] [Abstract][Full Text] [Related]
28. Adeno-associated viral-mediated gene transfer to hepatoma: thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals.
Su H; Lu R; Ding R; Kan YW
Mol Ther; 2000 Jun; 1(6):509-15. PubMed ID: 10933975
[TBL] [Abstract][Full Text] [Related]
29. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
30. [Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV(1)-TK/GCV) system as an effective "in vivo death switch" of live tumor vaccines].
Kang Y; Xu CJ; Liu XS; Wu CQ; Zhong CP; Gu JR
Ai Zheng; 2005 Aug; 24(8):909-14. PubMed ID: 16086864
[TBL] [Abstract][Full Text] [Related]
31. An experimental application of gene therapy for human retinoblastoma.
Hayashi N; Ido E; Ohtsuki Y; Ueno H
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):265-72. PubMed ID: 9950583
[TBL] [Abstract][Full Text] [Related]
32. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
[TBL] [Abstract][Full Text] [Related]
33. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
[TBL] [Abstract][Full Text] [Related]
34. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
[TBL] [Abstract][Full Text] [Related]
35. Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma.
Sakai Y; Kaneko S; Nakamoto Y; Kagaya T; Mukaida N; Kobayashi K
Cancer Gene Ther; 2001 Oct; 8(10):695-704. PubMed ID: 11687892
[TBL] [Abstract][Full Text] [Related]
36. HSV-tk gene therapy for human renal cell carcinoma in nude mice.
Pulkkanen KJ; Parkkinen JJ; Laukkanen JM; Kettunen MI; Tyynela K; Kauppinen RA; Ala-Opas MY; Yla-Herttuala S
Cancer Gene Ther; 2001 Jul; 8(7):529-36. PubMed ID: 11498775
[TBL] [Abstract][Full Text] [Related]
37. [Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo].
Kong BH; Wang WX; Liu CS; Ma DX; Qu X
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):195-8. PubMed ID: 12885362
[TBL] [Abstract][Full Text] [Related]
38. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
Wildner O; Morris JC
J Gene Med; 2000; 2(5):353-60. PubMed ID: 11045429
[TBL] [Abstract][Full Text] [Related]
39. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer.
Li PX; Ngo D; Brade AM; Klamut HJ
Cancer Gene Ther; 1999; 6(2):179-90. PubMed ID: 10195885
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells.
Rubsam LZ; Boucher PD; Murphy PJ; KuKuruga M; Shewach DS
Cancer Res; 1999 Feb; 59(3):669-75. PubMed ID: 9973216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
